Drug · CHEMBL506
PRIMAQUINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PRIMAQUINE. Drugs and targets, record CHEMBL506. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL506
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Kanaprim, Maliride, NSC-27296, Neo-quipenyl, Primachin, Primaquina, SN-13272, WR-2975
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases7
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| Plasmodium vivax malaria | Phase 3 | ClinicalTrials.gov | 31 | 31 | https://conductscience.org/library/drugs?q=MONDO_0005921 |
| malaria | Approval | ATC and TTD | 25 | 23 | https://conductscience.org/library/drugs?q=MONDO_0005136 |
| Plasmodium falciparum malaria | Phase 3 | ClinicalTrials.gov | 15 | 15 | https://conductscience.org/library/drugs?q=MONDO_0005920 |
| pneumocystosis | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0019121 |
| AIDS | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0012268 |
| G6PD deficiency | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005775 |
| anemia | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0002280 |
Source Open Targets
Trials127
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01376167 | Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse | Phase 2 | 851 | 2018-04-23 | primaquine | Its name | ClinicalTrials.gov |
| NCT04661579 | Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy | Phase 2 | 620 | 2024-07-19 | primaquine | Its name | ClinicalTrials.gov |
| NCT03610399 | Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of P. Vivax Malaria, Cruzeiro do Sul, Acre, Brazil | 257 | 2021-08-09 | primaquine | Its name | ClinicalTrials.gov | |
| NCT02216123 | Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria | Phase 3 | 251 | 2018-05-16 | primaquine | Its name | ClinicalTrials.gov |
| NCT02992119 | Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults | Phase 2 | 193 | 2019-07-29 | primaquine | Its name | ClinicalTrials.gov |
| NCT02389374 | A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh | Phase 4 | 181 | 2017-08-18 | primaquine | Its name | ClinicalTrials.gov |
| NCT02802501 | Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria | Phase 3 | 150 | 2020-07-24 | primaquine | Its name | ClinicalTrials.gov |
| NCT05252845 | Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults | Phase 2 | 127 | 2025-07-03 | primaquine | Its name | ClinicalTrials.gov |
| NCT02043652 | Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil | 119 | 2018-02-07 | primaquine | Its name | ClinicalTrials.gov | |
| NCT02851108 | Methylene Blue Against Falciparum Malaria in Burkina Faso | Phase 2 | 100 | 2020-03-25 | primaquine | Its name | ClinicalTrials.gov |
1 to 10 of 127
See all 127 trialsComparisons in its trials19
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| TQ+CQ vs PQ+CQ: Number of Participants With P. Falciparum | 4 of 166 | 3 of 85 | 251 | NCT02216123 | Trial comparisons |
| TQ+CQ vs PQ+CQ: Number of Participants With Recrudescence | 0 of 166 | 0 of 85 | 251 | NCT02216123 | Trial comparisons |
| TQ+CQ vs PQ+CQ: deaths from any cause | 0 of 166 | 0 of 85 | 251 | NCT02216123 | Trial comparisons |
| TQ+CQ vs PQ+CQ: serious adverse events | 6 of 166 | 1 of 85 | 251 | NCT02216123 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: deaths from any cause | 0 of 84 | 0 of 75 | 159 | NCT04222088 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: serious adverse events | 0 of 84 | 0 of 75 | 159 | NCT04222088 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: Adequate Clinical and Parasitological Response (ACPR) | 74 of 75 | 72 of 74 | 149 | NCT04222088 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: Early Treatment Failure (ETF) | 0 of 75 | 0 of 74 | 149 | NCT04222088 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: Late Clinical Failure (LCF) | 1 of 75 | 0 of 74 | 149 | NCT04222088 | Trial comparisons |
| Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: Late Parasitological Failure (LPF) | 0 of 75 | 2 of 74 | 149 | NCT04222088 | Trial comparisons |
1 to 10 of 19
See all 19 comparisons in its trialsPapers from its trials149
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL506
GET https://conductscience.org/api/drugs/v1/CHEMBL506/trials?page=2